NCT04715022RecruitingPhase 1/2
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance
Source: ClinicalTrials.gov · Last updated 8 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD). This study is testing the health of the blood vessels and the activity of the nerves that control the blood vessels in adults with insulin resistance. The extent to which ascorbic acid (Vitamin C) improves the function of the blood vessels will be determined. The primary outcome is blood pressure, which is the result of blood vessel health and activity of the nerves, and the reduction in blood pressure that is observed with ascorbic acid.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- First submitted
- 10 Jan 2021
- Start date
- 17 Jun 2021
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Obesity, High blood pressure
- NCT number
- NCT04715022
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 23
- From 17 Jun 2021 to the primary completion date, 1 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking a statin or antihypertension medication
Other illness
- Hypertension: \<130/80 mmHg
- History of heart disease (e.g., myocardial infarction, stent)
- History of vascular disease (e.g., bypass, stroke)
Lab values
- Diabetes mellitus: fasting glucose \< 1267 mg/dL and/or HbA1c \< 6.5%
- Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
Who the study is looking for
- Obese: BMI \>30 m/kg2
- Middle-aged: 35-65 years
- Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
- Able and willing to provide written informed consent
Age in the registry: 35 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.